Source comparison
Tesamorelin + Ipamorelin Blend Enhanced GH Release: Mechanism Comparison
Primary Receptor Target GHRH receptors (GHRHR) on anterior pituitary somatotrophs Ghrelin receptors (GHSR-1a) on pituitary and hypothalamus Dual-receptor activation creates overlapping but non-redundant signaling cascades Non-overlapping pathways allow synergi
This comparison does not assign a generated winner or score.
- Primary Receptor Target
- GHRH receptors (GHRHR) on anterior pituitary somatotrophs
- Ghrelin receptors (GHSR-1a) on pituitary and hypothalamus
- Dual-receptor activation creates overlapping but non-redundant signaling cascades
- Non-overlapping pathways allow synergistic rather than additive effects
- Peak GH Amplitude
- 2.5–4× baseline within 60–90 minutes
- 3–5× baseline within 45–60 minutes
- 4–7× baseline with extended duration (4–6 hours vs 2–3 hours monotherapy)
- Amplitude boost is clinically significant for lipolysis and anabolic signaling
- Cortisol/Prolactin Response
- Minimal (GHRH pathway is GH-selective)
- Negligible (ipamorelin is highly selective; no ACTH or prolactin stimulation)
- Both peptides maintain selectivity in combination. No cortisol spike observed in dual protocols
- Critical advantage over GHRP-6 or GHRP-2, which elevate cortisol 15–25%
- Somatostatin Feedback
- Triggers compensatory GHIH rise after 90–120 minutes, suppressing further GH release
- Ghrelin pathway partially overrides somatostatin inhibition via independent signaling
- Ipamorelin sustains tesamorelin's effect by delaying somatostatin-mediated suppression
- This is the mechanistic basis for the blend's prolonged pulse duration
- Half-Life
- Approximately 38 minutes (plasma)
- Approximately 2 hours (plasma)
- Staggered clearance maintains receptor occupancy across 4–6 hour window
- Ipamorelin's longer half-life extends the effective GH release window post-tesamorelin peak